Peripheral Intravascular Lithotripsy (IVL) Market Size, Share, and Trends Analysis | Global | 2025-2032
Description
Global Intravascular Lithotripsy Market Report
By iData Research - 48 pages - 4 charts, 20 figures
Executive Summary
The global intravascular lithotripsy market was valued at $335 million in 2025. Over the forecast period, the market is expected to grow at a CAGR of 23.3% to reach $1.4 billion by 2032.
This report provides focused analysis of the global IVL market, including unit sales, procedure numbers, average selling prices, market size, market shares, growth trends and market forecasts. It also includes detailed discussion of market drivers and limiters, recent mergers and acquisitions, company profiles, product portfolios and leading competitors. Although the category remains relatively narrow compared with broader peripheral vascular device markets, IVL is one of the fastest-growing segments due to its clinical relevance in calcified lesions and its expanding role in complex endovascular intervention.
Intravascular lithotripsy is gaining traction because it offers a targeted way to modify calcium while minimizing trauma to the vessel wall. This makes it especially attractive in procedures where vessel preparation matters and where conventional ballooning, stenting or atherectomy may be less desirable or less effective. As physicians become more familiar with the technology and as supporting clinical data expands, IVL is moving from a newer niche treatment into a more established option for calcium management.
Despite this strong growth profile, the market is still shaped by high cost. Relative to atherectomy devices, lithotripsy balloons sell at a substantial premium. Capital costs can also make adoption more selective at the account level, particularly in care settings where procedure volumes need to justify the investment. Even so, expanding indications and growing physician awareness are gradually reducing some of these barriers, helping support the rapid rise of the IVL market.
Market Overview
The global intravascular lithotripsy market includes catheter-based devices designed to fracture vascular calcium through localized sonic pressure waves before or during balloon dilation. The technology was developed to address one of the most difficult challenges in endovascular intervention: severe calcification. In calcified lesions, standard balloons may not fully expand, stents may not appose properly and atherectomy may carry added procedural complexity or risk. IVL offers an alternative method of lesion preparation that focuses on modifying calcium while limiting damage to surrounding tissue.
This market has grown quickly because calcified peripheral and coronary disease remains a major clinical challenge. As patient populations age and as diabetes, renal disease and other cardiovascular risk factors remain prevalent, the burden of heavily calcified lesions continues to rise. These patients often require more advanced lesion preparation tools, which creates a strong need for technologies that can make treatment safer and more predictable.
The IVL market also reflects a broader movement toward precision-based endovascular care. Physicians increasingly want lesion preparation technologies that improve procedural control, reduce complications and support better downstream outcomes. In this setting, IVL has gained attention because it addresses calcium in a way that is compatible with other treatment tools and can often fit smoothly into existing workflows.
At the same time, the market is still relatively concentrated and early in its development compared with more mature vascular categories. That combination of strong clinical need, expanding use cases and limited competitive saturation is a key reason why IVL is projected to grow so quickly through 2032.
Market Drivers
Strong Clinical Evidence
One of the most important drivers in the global intravascular lithotripsy market is the strength of the available clinical evidence. With multiple clinical trials already completed and additional studies ongoing, IVL has built a meaningful body of support that helps physicians understand where and how the technology can be used effectively. For a newer and premium-priced device category, strong evidence is essential because it reduces hesitation and gives clinicians more confidence in changing treatment patterns.
Clinical evidence also supports market expansion by helping newer users become comfortable with the technology. For physicians who are less familiar with IVL, well-structured trial data can validate the safety profile, procedural utility and anatomical compatibility of the device. This not only supports direct adoption but also increases visibility within the broader interventional community.
Expanding Clinical Options
Another major growth driver is the expansion of clinical options. As IVL obtained indications for peripheral, coronary and below-the-knee use, its relevance across vascular intervention increased significantly. Rather than being limited to one procedural niche, IVL can now be considered across a wider range of lesion types and anatomical territories.
This matters because every additional use case improves the commercial logic of adoption. When hospitals or physician groups can use IVL across multiple procedures, the technology becomes easier to justify. More procedures also mean more opportunities to generate evidence, refine best practices and identify further compatible applications. This expanding clinical footprint is one of the strongest reasons why the market is growing at such a high rate.
EVAR and TAVR Procedure Support
IVL is also benefiting from its increasing role in endovascular aortic repair, or EVAR, and transcatheter aortic valve replacement, or TAVR, procedures. These procedures require reliable femoral access to the aorta, often with large French devices. In patients with calcified iliac or femoral arteries, access can be difficult or risky. Because IVL can reduce calcium-related resistance while maintaining low vessel trauma, it is becoming an important access-enabling tool in these cases.
This is a meaningful market driver because EVAR and TAVR are high-value procedures where access success is critical. As IVL use in these procedures grows, it expands the technology’s importance beyond peripheral lesion preparation and into structural and aortic intervention workflows. That gives the market another layer of procedural relevance.
Market Limiters
Expensive Technology
The largest limiter in the global IVL market is the cost of the technology. Relative to atherectomy devices, lithotripsy balloons carry a substantial premium. In addition to per-balloon pricing, capital costs can also influence adoption. Care settings that want to control per-procedure economics may limit use to selected cases, especially early in adoption. This makes some clinics hesitant to start using the technology unless volumes are high enough to justify the investment.
As indications continue to expand and as IVL becomes compatible with more procedure types, some of these barriers are reduced. Still, the high cost per balloon remains a major consideration. In many accounts, the clinical value may be clear, but economic evaluation still shapes how often the product is used and which patients receive it.
Increasing Competition
Another important limiter is growing competition, especially from atherectomy devices in office-based labs and other cost-sensitive settings. Large companies with broad peripheral vascular portfolios are increasingly aggressive in pursuing atherectomy exclusivity, often using that position to drive additional product sales across an account. Because IVL also addresses calcium, it competes for a similar clinical problem even if the technologies work differently.
This competition is especially relevant in outpatient settings where economics, portfolio contracting and physician familiarity strongly influence device choice. IVL may offer clear clinical advantages in some lesions, but its adoption can still be constrained if accounts are already aligned around other plaque modification strategies.
Selective Use Driven by Economics
The IVL market is also limited by the fact that the technology is often used selectively rather than universally. Even in accounts that have adopted IVL, clinicians may reserve it for cases where calcium burden is severe enough to justify the cost. That means market growth depends not just on whether a site has access to the technology, but also on how often physicians choose to deploy it. This selective use pattern can slow penetration even in markets where physician awareness is rising.
Market Coverage and Data Scope
Quantitative Coverage
Market size, market shares, market forecasts, market growth rates, units sold and average selling prices.
Qualitative Coverage
Market drivers and limiters, market size and growth trends, recent mergers and acquisitions, company profiles, product portfolios and leading competitors.
Time Frame
Base year 2025, historical data to 2022 and forecasts through 2032.
Regional Coverage
North America, Latin America, Western Europe, Central and Eastern Europe, the Middle East, Asia-Pacific and Africa.
Data Types Included
Unit sales, average selling prices, procedure numbers, market size and growth trends.
This report is designed to support strategic planning, competitive benchmarking and commercial assessment by combining pricing and unit analysis with practical clinical and market context.
Markets Covered and Segmentation
The report covers the Global Intravascular Lithotripsy Market.
Competitive Analysis
In May 2024, Johnson & Johnson completed its acquisition of Shockwave Medical, further strengthening Johnson & Johnson MedTech’s leadership in cardiovascular intervention. This transaction is strategically important because Shockwave Medical was the sole competitor in the IVL market and the company that established the category.
Shockwave Medical’s flagship product, the Peripheral Lithoplasty Balloon Dilation Catheter, first received FDA approval for peripheral use in September 2016. Since then, the company has built the market through clinical development, regulatory expansion and physician education. Key clinical programs have included the DISRUPT II and III trials in the femoral-popliteal artery, as well as the DISRUPT BTK and BTK II trials evaluating IVL below the knee. In September 2019, Shockwave’s Lithoplasty balloon also gained FDA approval for coronary use, extending the company’s reach and reinforcing IVL as a multi-application technology.
Because Shockwave Medical has effectively defined the category, its commercial performance has been tied closely to overall market expansion. The company’s advantage comes not only from being first to market, but also from building strong evidence, widening indications and making IVL more familiar across interventional specialties. With Johnson & Johnson MedTech now owning the platform, the category is positioned to benefit from broader commercial reach and stronger integration into global cardiovascular portfolios.
At present, the competitive landscape remains highly concentrated. This is unusual compared with more mature vascular device categories, but it also reflects how early and differentiated the IVL segment still is.
Technology and Practice Trends
One of the clearest trends in the IVL market is the growing use of lithotripsy for calcium modification in complex lesions. Physicians are increasingly recognizing that IVL can improve vessel compliance while keeping wall trauma relatively low.
Another important trend is the widening use of IVL across different anatomical settings. Peripheral use remains central, but coronary and below-the-knee applications are helping broaden the market. Access support before EVAR and TAVR is another growing practice trend.
Clinical workflow integration is also improving. As physicians gain experience with IVL, the technology is being incorporated more naturally into lesion preparation strategies alongside balloons, stents and other adjunctive tools.
Finally, strong evidence generation remains central to market development. Ongoing studies continue to shape physician perception and expand the set of clinical scenarios where IVL is considered an appropriate and effective treatment option.
Geography
This report provides global coverage across North America, Europe, Asia-Pacific, Latin America, the Middle East, and Africa.
Deliverables
48 pages of detailed market analysis, forecasts and category-level discussion.
4 charts and 20 figures covering market performance, regional trends and competitive positioning.
Methodology Appendix and Acronym Glossary.
Licensing options include single-user, site and enterprise.
Why This Report
Where are the fastest-growing opportunities in the global intravascular lithotripsy market?
How are expanding indications in peripheral, coronary and below-the-knee procedures affecting long-term demand?
What role does IVL play in EVAR and TAVR access preparation, and how important is that opportunity?
How do premium pricing and capital costs affect adoption across hospitals, office-based labs and other care settings?
How concentrated is the competitive landscape, and what does Johnson & Johnson’s acquisition of Shockwave Medical mean for the category?
How are clinical evidence, physician awareness and calcium management needs shaping market growth through 2032?
The Global Intravascular Lithotripsy Market Report from iData Research answers these questions with detailed market sizing, pricing analysis, competitive intelligence and forecast modeling. Use it to evaluate opportunity, benchmark category growth and support strategy in one of the fastest-growing segments of complex vascular intervention.
About iData Research
iData Research is a premium market intelligence firm headquartered in Canada with offices across North America and Europe.
Over the last 20 years, the company has specialized in device-level sizing, procedure models, pricing trends, and competitive share across MedTech.
Since 2005, iData has supported global OEMs, mid-market innovators, and investors with triangulated data based on units and ASPs, with country-level forecasts and analyst access across Europe, North America, Latin America, the Middle East, Africa, and APAC.
By iData Research - 48 pages - 4 charts, 20 figures
Executive Summary
The global intravascular lithotripsy market was valued at $335 million in 2025. Over the forecast period, the market is expected to grow at a CAGR of 23.3% to reach $1.4 billion by 2032.
This report provides focused analysis of the global IVL market, including unit sales, procedure numbers, average selling prices, market size, market shares, growth trends and market forecasts. It also includes detailed discussion of market drivers and limiters, recent mergers and acquisitions, company profiles, product portfolios and leading competitors. Although the category remains relatively narrow compared with broader peripheral vascular device markets, IVL is one of the fastest-growing segments due to its clinical relevance in calcified lesions and its expanding role in complex endovascular intervention.
Intravascular lithotripsy is gaining traction because it offers a targeted way to modify calcium while minimizing trauma to the vessel wall. This makes it especially attractive in procedures where vessel preparation matters and where conventional ballooning, stenting or atherectomy may be less desirable or less effective. As physicians become more familiar with the technology and as supporting clinical data expands, IVL is moving from a newer niche treatment into a more established option for calcium management.
Despite this strong growth profile, the market is still shaped by high cost. Relative to atherectomy devices, lithotripsy balloons sell at a substantial premium. Capital costs can also make adoption more selective at the account level, particularly in care settings where procedure volumes need to justify the investment. Even so, expanding indications and growing physician awareness are gradually reducing some of these barriers, helping support the rapid rise of the IVL market.
Market Overview
The global intravascular lithotripsy market includes catheter-based devices designed to fracture vascular calcium through localized sonic pressure waves before or during balloon dilation. The technology was developed to address one of the most difficult challenges in endovascular intervention: severe calcification. In calcified lesions, standard balloons may not fully expand, stents may not appose properly and atherectomy may carry added procedural complexity or risk. IVL offers an alternative method of lesion preparation that focuses on modifying calcium while limiting damage to surrounding tissue.
This market has grown quickly because calcified peripheral and coronary disease remains a major clinical challenge. As patient populations age and as diabetes, renal disease and other cardiovascular risk factors remain prevalent, the burden of heavily calcified lesions continues to rise. These patients often require more advanced lesion preparation tools, which creates a strong need for technologies that can make treatment safer and more predictable.
The IVL market also reflects a broader movement toward precision-based endovascular care. Physicians increasingly want lesion preparation technologies that improve procedural control, reduce complications and support better downstream outcomes. In this setting, IVL has gained attention because it addresses calcium in a way that is compatible with other treatment tools and can often fit smoothly into existing workflows.
At the same time, the market is still relatively concentrated and early in its development compared with more mature vascular categories. That combination of strong clinical need, expanding use cases and limited competitive saturation is a key reason why IVL is projected to grow so quickly through 2032.
Market Drivers
Strong Clinical Evidence
One of the most important drivers in the global intravascular lithotripsy market is the strength of the available clinical evidence. With multiple clinical trials already completed and additional studies ongoing, IVL has built a meaningful body of support that helps physicians understand where and how the technology can be used effectively. For a newer and premium-priced device category, strong evidence is essential because it reduces hesitation and gives clinicians more confidence in changing treatment patterns.
Clinical evidence also supports market expansion by helping newer users become comfortable with the technology. For physicians who are less familiar with IVL, well-structured trial data can validate the safety profile, procedural utility and anatomical compatibility of the device. This not only supports direct adoption but also increases visibility within the broader interventional community.
Expanding Clinical Options
Another major growth driver is the expansion of clinical options. As IVL obtained indications for peripheral, coronary and below-the-knee use, its relevance across vascular intervention increased significantly. Rather than being limited to one procedural niche, IVL can now be considered across a wider range of lesion types and anatomical territories.
This matters because every additional use case improves the commercial logic of adoption. When hospitals or physician groups can use IVL across multiple procedures, the technology becomes easier to justify. More procedures also mean more opportunities to generate evidence, refine best practices and identify further compatible applications. This expanding clinical footprint is one of the strongest reasons why the market is growing at such a high rate.
EVAR and TAVR Procedure Support
IVL is also benefiting from its increasing role in endovascular aortic repair, or EVAR, and transcatheter aortic valve replacement, or TAVR, procedures. These procedures require reliable femoral access to the aorta, often with large French devices. In patients with calcified iliac or femoral arteries, access can be difficult or risky. Because IVL can reduce calcium-related resistance while maintaining low vessel trauma, it is becoming an important access-enabling tool in these cases.
This is a meaningful market driver because EVAR and TAVR are high-value procedures where access success is critical. As IVL use in these procedures grows, it expands the technology’s importance beyond peripheral lesion preparation and into structural and aortic intervention workflows. That gives the market another layer of procedural relevance.
Market Limiters
Expensive Technology
The largest limiter in the global IVL market is the cost of the technology. Relative to atherectomy devices, lithotripsy balloons carry a substantial premium. In addition to per-balloon pricing, capital costs can also influence adoption. Care settings that want to control per-procedure economics may limit use to selected cases, especially early in adoption. This makes some clinics hesitant to start using the technology unless volumes are high enough to justify the investment.
As indications continue to expand and as IVL becomes compatible with more procedure types, some of these barriers are reduced. Still, the high cost per balloon remains a major consideration. In many accounts, the clinical value may be clear, but economic evaluation still shapes how often the product is used and which patients receive it.
Increasing Competition
Another important limiter is growing competition, especially from atherectomy devices in office-based labs and other cost-sensitive settings. Large companies with broad peripheral vascular portfolios are increasingly aggressive in pursuing atherectomy exclusivity, often using that position to drive additional product sales across an account. Because IVL also addresses calcium, it competes for a similar clinical problem even if the technologies work differently.
This competition is especially relevant in outpatient settings where economics, portfolio contracting and physician familiarity strongly influence device choice. IVL may offer clear clinical advantages in some lesions, but its adoption can still be constrained if accounts are already aligned around other plaque modification strategies.
Selective Use Driven by Economics
The IVL market is also limited by the fact that the technology is often used selectively rather than universally. Even in accounts that have adopted IVL, clinicians may reserve it for cases where calcium burden is severe enough to justify the cost. That means market growth depends not just on whether a site has access to the technology, but also on how often physicians choose to deploy it. This selective use pattern can slow penetration even in markets where physician awareness is rising.
Market Coverage and Data Scope
Quantitative Coverage
Market size, market shares, market forecasts, market growth rates, units sold and average selling prices.
Qualitative Coverage
Market drivers and limiters, market size and growth trends, recent mergers and acquisitions, company profiles, product portfolios and leading competitors.
Time Frame
Base year 2025, historical data to 2022 and forecasts through 2032.
Regional Coverage
North America, Latin America, Western Europe, Central and Eastern Europe, the Middle East, Asia-Pacific and Africa.
Data Types Included
Unit sales, average selling prices, procedure numbers, market size and growth trends.
This report is designed to support strategic planning, competitive benchmarking and commercial assessment by combining pricing and unit analysis with practical clinical and market context.
Markets Covered and Segmentation
The report covers the Global Intravascular Lithotripsy Market.
Competitive Analysis
In May 2024, Johnson & Johnson completed its acquisition of Shockwave Medical, further strengthening Johnson & Johnson MedTech’s leadership in cardiovascular intervention. This transaction is strategically important because Shockwave Medical was the sole competitor in the IVL market and the company that established the category.
Shockwave Medical’s flagship product, the Peripheral Lithoplasty Balloon Dilation Catheter, first received FDA approval for peripheral use in September 2016. Since then, the company has built the market through clinical development, regulatory expansion and physician education. Key clinical programs have included the DISRUPT II and III trials in the femoral-popliteal artery, as well as the DISRUPT BTK and BTK II trials evaluating IVL below the knee. In September 2019, Shockwave’s Lithoplasty balloon also gained FDA approval for coronary use, extending the company’s reach and reinforcing IVL as a multi-application technology.
Because Shockwave Medical has effectively defined the category, its commercial performance has been tied closely to overall market expansion. The company’s advantage comes not only from being first to market, but also from building strong evidence, widening indications and making IVL more familiar across interventional specialties. With Johnson & Johnson MedTech now owning the platform, the category is positioned to benefit from broader commercial reach and stronger integration into global cardiovascular portfolios.
At present, the competitive landscape remains highly concentrated. This is unusual compared with more mature vascular device categories, but it also reflects how early and differentiated the IVL segment still is.
Technology and Practice Trends
One of the clearest trends in the IVL market is the growing use of lithotripsy for calcium modification in complex lesions. Physicians are increasingly recognizing that IVL can improve vessel compliance while keeping wall trauma relatively low.
Another important trend is the widening use of IVL across different anatomical settings. Peripheral use remains central, but coronary and below-the-knee applications are helping broaden the market. Access support before EVAR and TAVR is another growing practice trend.
Clinical workflow integration is also improving. As physicians gain experience with IVL, the technology is being incorporated more naturally into lesion preparation strategies alongside balloons, stents and other adjunctive tools.
Finally, strong evidence generation remains central to market development. Ongoing studies continue to shape physician perception and expand the set of clinical scenarios where IVL is considered an appropriate and effective treatment option.
Geography
This report provides global coverage across North America, Europe, Asia-Pacific, Latin America, the Middle East, and Africa.
Deliverables
48 pages of detailed market analysis, forecasts and category-level discussion.
4 charts and 20 figures covering market performance, regional trends and competitive positioning.
Methodology Appendix and Acronym Glossary.
Licensing options include single-user, site and enterprise.
Why This Report
Where are the fastest-growing opportunities in the global intravascular lithotripsy market?
How are expanding indications in peripheral, coronary and below-the-knee procedures affecting long-term demand?
What role does IVL play in EVAR and TAVR access preparation, and how important is that opportunity?
How do premium pricing and capital costs affect adoption across hospitals, office-based labs and other care settings?
How concentrated is the competitive landscape, and what does Johnson & Johnson’s acquisition of Shockwave Medical mean for the category?
How are clinical evidence, physician awareness and calcium management needs shaping market growth through 2032?
The Global Intravascular Lithotripsy Market Report from iData Research answers these questions with detailed market sizing, pricing analysis, competitive intelligence and forecast modeling. Use it to evaluate opportunity, benchmark category growth and support strategy in one of the fastest-growing segments of complex vascular intervention.
About iData Research
iData Research is a premium market intelligence firm headquartered in Canada with offices across North America and Europe.
Over the last 20 years, the company has specialized in device-level sizing, procedure models, pricing trends, and competitive share across MedTech.
Since 2005, iData has supported global OEMs, mid-market innovators, and investors with triangulated data based on units and ASPs, with country-level forecasts and analyst access across Europe, North America, Latin America, the Middle East, Africa, and APAC.
Table of Contents
32 Pages
- List Of Figures
- List Of Charts
- Research Methodology
- Step 1: Project Initiation & Team Selection
- Step 2: Prepare Data Systems And Perform Secondary Research
- Step 3: Preparation For Interviews & Questionnaire Design
- Step 4: Performing Primary Research
- Step 5: Research Analysis: Establishing Baseline Estimates
- Step 6: Market Forecast And Analysis
- Step 7: Identify Strategic Opportunities
- Step 8: Final Review And Market Release
- Step 9: Customer Feedback And Market Monitoring
- Impact Of Global Tariffs
- Intravascular Lithotripsy Market
- 8.1 Executive Summary
- 8.1.1 Global Intravascular Lithotripsy Market Overview
- 8.1.2 Competitive Analysis
- 8.1.3 Procedures Included
- 8.1.4 Regions Included
- 8.2 Introduction
- 8.3 Procedure Numbers
- 8.4 Market Analysis And Forecast
- 8.5 Drivers And Limiters
- 8.5.1 Market Drivers
- 8.5.2 Market Limiters
- 8.6 Competitive Market Share Analysis
- Abbreviations
- Chart 8-1: Intravascular Lithotripsy Market, Global, 2025 & 2032
- Chart 8-2: Intravascular Lithotripsy Procedures, Global, 2025
- Chart 8-3: Intravascular Lithotripsy Procedures by Region, Global, 2022 – 2032
- Chart 8-4: Intravascular Lithotripsy Market, Global, 2022 – 2032
- Figure 8-1: Intravascular Lithotripsy Procedures Covered
- Figure 8-2: Intravascular Lithotripsy Regions Covered, Global (1 of 2)
- Figure 8-3: Intravascular Lithotripsy Regions Covered, Global (2 of 2)
- Figure 8-4: Intravascular Lithotripsy Procedures by Region, Global, 2022 – 2032
- Figure 8-5: Intravascular Lithotripsy Procedures by Country, North America, 2022 – 2032
- Figure 8-6: Intravascular Lithotripsy Procedures by Country, Latin America, 2022 – 2032 (1 of 2)
- Figure 8-7: Intravascular Lithotripsy Procedures by Country, Latin America, 2022 – 2032 (2 of 2)
- Figure 8-8: Intravascular Lithotripsy Procedures by Country, Western Europe, 2022 – 2032
- Figure 8-9: Intravascular Lithotripsy Procedures by Country, Central & Eastern Europe, 2022 – 2032 (1 of 2)
- Figure 8-10: Intravascular Lithotripsy Procedures by Country, Central & Eastern Europe, 2022 – 2032 (2 of 2)
- Figure 8-11: Intravascular Lithotripsy Procedures by Country, Middle East, 2022 – 2032
- Figure 8-12: Intravascular Lithotripsy Procedures by Country, Asia-Pacific, 2022 – 2032 (1 of 3)
- Figure 8-13: Intravascular Lithotripsy Procedures by Country, Asia-Pacific, 2022 – 2032 (2 of 3)
- Figure 8-14: Intravascular Lithotripsy Procedures by Country, Asia-Pacific, 2022 – 2032 (3 of 3)
- Figure 8-15: Intravascular Lithotripsy Procedures by Country, Africa, 2022 – 2032
- Figure 8-16: Intravascular Lithotripsy Market, Global, 2022 – 2032
- Figure 8-17: Units Sold by Region, Intravascular Lithotripsy Market, Global, 2022 – 2032
- Figure 8-18: Average Selling Price by Region, Intravascular Lithotripsy Market, Global, 2022 – 2032 (US$)
- Figure 8-19: Market Value by Region, Intravascular Lithotripsy Market, Global, 2022 – 2032 (US$M)
- Figure 8-20: Leading Competitors, Intravascular Lithotripsy Market, Global, 2025
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
